Sitagliptin: Clinical Trials

50 trials of Sitagliptin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 4 terminated, 3 unknown, 2 not yet recruiting. 50 Phase 2, 7 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 250Completed 37, Terminated 4, Unknown 3, Not yet recruiting 2, Recruiting 2, Withdrawn 2
Phase 37Completed 6, Not yet recruiting 1
Phase 14Completed 2, Unknown 1, Withdrawn 1

Follow Sitagliptin: new trials by email Literature Review of Sitagliptin trials Research Report on Sitagliptin

Trials (filtered) newest first · largest first

All 50 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease
Sitagliptin, Sitagliptin placebo - Parkinson Disease
Phase 2Not yet recruitingYonsei University1602026-12-152026-09-10
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer
Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University802026-07-012026-07-21
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Sitagliptin - Glioblastoma, Brain Tumor
Phase 2RecruitingCase Comprehensive Cancer Center482026-03-162026-11-17
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Sitagliptin, Bortezomib, Cyclophosphamide - Bone Marrow Transplant Complications, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnIndiana University2023-11-012024-04-29
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
DA-1241, Sitagliptin, DA-1241 Placebo - NON-ALCOHOLIC STEATOHEPATITIS
Phase 2CompletedNeuroBo Pharmaceuticals Inc.1092023-09-142024-11-14
Effects of Sitagliptin in Relatives of T1D Patients
Sitagliptin, Professional CGM - Type 1 Diabetes
Phase 2 / Phase 3Not yet recruitingUniversity of Milan702023-07-012023-05-10
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
Metformin Extended Release Oral Tablet, Sitagliptin - Type 1 Diabetes, Monogenic Diabetes
Phase 2 / Phase 3CompletedJoslin Diabetes Center32021-08-262025-02-24
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Sitagliptin, Danazol - Immune Thrombocytopenia, Blood Coagulation Disorders
Phase 2UnknownPeking University People's Hospital1202021-06-012022-04-29
Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients
placebo, metformin, Sitagliptin - Polycystic Ovary Syndrome, Infertility
Phase 1 / Phase 2UnknownShahid Beheshti University of Medical Sciences802020-01-102021-03-22
Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
Evogliptin, Sitagliptin, Placebo Evogliptin - Diabetes Mellitus, Type 2
Phase 2CompletedEurofarma Laboratorios S.A.1462017-08-082018-08-14
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Sitagliptin - Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Phase 2CompletedSherif S. Farag372016-02-032021-01-22
Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity
Sitagliptin, Placebo - Atherosclerosis, Inflammation
Phase 2CompletedUniversity of Southern California212016-01-012019-07-17
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
LIK066, Sitagliptin, Placebo - Type 2 Diabetes Mellitus
Phase 2WithdrawnNovartis Pharmaceuticals2015-11-012014-04-03
Sitagliptin for Reducing Inflammation and Immune Activation
Sitagliptin, Placebo for sitagliptin - HIV-1 Infection
Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections902015-09-012018-06-18
Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes
Sitagliptin, Placebo - Gastroparesis, Diabetes Mellitus
Phase 2CompletedRoyal Adelaide Hospital142015-07-012017-07-07
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
GSK2330672, Placebo, Sitagliptin - Diabetes Mellitus, Type 2
Phase 2CompletedGlaxoSmithKline702014-08-272017-11-06
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
Sitagliptin, Gliclazide, Sitagliptin matched placebo - Psoriasis, Type 2 Diabetes Mellitus
Phase 2CompletedUniversity College Dublin202014-04-012020-05-14
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
LY2409021, Sitagliptin, Placebo - Diabetes Mellitus, Type 2
Phase 2TerminatedEli Lilly and Company1742014-04-012019-10-09
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Sitagliptin, Placebo - Non-alcoholic Fatty Liver Disease
Phase 2CompletedUniversity of California, San Diego502014-01-012016-10-20
Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes
Sitagliptin, Exercise - Diabetes Mellitus Type 1
Phase 2CompletedUniversity Hospital, Basel, Switzerland242013-11-012017-07-27

Showing 20 of 50. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (22)  ·  Diabetes Mellitus (8)  ·  Diabetes Mellitus, Type 1 (6)  ·  Leukemia, Myeloid, Acute (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Glucose Intolerance (2)  ·  Inflammation (2)  ·  Insulin Resistance (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Myelodysplastic Syndromes (2)  ·  Non-alcoholic Fatty Liver Disease (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Atherosclerosis (1)  ·  Blood Coagulation Disorders (1)

Sponsors

Novartis Pharmaceuticals (4)  ·  Boehringer Ingelheim (3)  ·  GlaxoSmithKline (3)  ·  Eli Lilly and Company (2)  ·  Indiana University (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Sherif S. Farag (2)  ·  Takeda (2)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1)  ·  Case Comprehensive Cancer Center (1)  ·  Eurofarma Laboratorios S.A. (1)  ·  European Foundation for the Study of Diabetes (1)  ·  Gilead Sciences (1)  ·  Johns Hopkins University (1)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)

Countries

United States (27)  ·  Canada (7)  ·  Germany (7)  ·  Italy (5)  ·  Romania (5)  ·  India (4)  ·  Mexico (4)  ·  Poland (4)  ·  Puerto Rico (4)  ·  Russia (4)  ·  Taiwan (4)  ·  Argentina (3)  ·  Austria (3)  ·  China (3)  ·  Czechia (3)

Top investigators

Sherif Farag, MD, PhD (2)  ·  Alin Stirban, MD (1)  ·  Balow James, MD (1)  ·  Bernard Zinman, MD (1)  ·  Brian Kirby, MBBChBAOMD (1)  ·  Brian Roberts, MD (1)  ·  Dariush Elahi, PhD (1)  ·  David Peereboom, MD (1)  ·  Fred Sattler, MD (1)  ·  Gary Lewis, MD (1)

Results publications

PMID 24432999, PMID 24699248, PMID 10752702, PMID 19073764, PMID 19689275, PMID 21636800, PMID 22492586, PMID 22548646, PMID 22632452, PMID 22761275, PMID 23264399, PMID 23270493, PMID 23294774, PMID 23780460, PMID 23940010, PMID 24186878, PMID 24550217, PMID 24584549, PMID 24762094, PMID 25229125, PMID 25495067, PMID 25912221, PMID 26362564, PMID 26404926, PMID 26691396, PMID 27087519, PMID 27161178, PMID 27612849, PMID 28191913, PMID 28755389, PMID 28929327, PMID 30707388, PMID 30895467, PMID 31180194, PMID 31442575, PMID 31890041, PMID 32720198, PMID 33406328, PMID 33475138, PMID 3517648, PMID 35472672, PMID 36318027, PMID 36894938

NIH funding

2008 (1), R01HL112669 (1), UM1AI068636 (1)